{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:02:01Z","timestamp":1767139321094,"version":"build-2238731810"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Omburtamab is a B7H3-specific murine monoclonal antibody. B7H3 (CD 276) is a member of the B7 family of immune checkpoint co-inhibitory receptors overexpressed on many human malignancies. Radioimmunotherapy with\n                    <jats:sup>124<\/jats:sup>\n                    I- or\n                    <jats:sup>131<\/jats:sup>\n                    I-omburtamab administered in the cerebrospinal fluid (CSF), intraperitoneal or intratumoral cavity is currently under investigation for the treatment of CNS malignancies. The immunologic effects of anti-B7H3 therapy are not fully elucidated. A 6-year-old male was diagnosed with metastates of neuroblastoma to the received intraventricular\n                    <jats:sup>131<\/jats:sup>\n                    I-omburtamab on an IRB-approved protocol. A treatment cycle consisted of a 2\u00a0mCi dosimetry dose and a 50\u00a0mCi treatment dose. Dosimetry by serial imaging, pharmacokinetics and safety were investigated. Clinical status, magnetic resonance imaging, CSF cell count and cytology were evaluated pre- and post-\n                    <jats:sup>131<\/jats:sup>\n                    I-omburtamab at 5 and 26\u00a0weeks. The patient did well with cycle 1. Three hours after the dosimetry dose of cycle 2, he developed a fever (39\u00a0\u00b0C), chills and headache. Blood and CSF samples were sent for culture. CSF was notable for nucleated cell pleocytosis with profound mast cell proliferation consistent with chemical meningitis. He was treated with supportive care; symptoms resolved over 48\u00a0h. Further therapy with\n                    <jats:sup>131<\/jats:sup>\n                    I-omburtamab was electively discontinued. CSF cell count 5\u00a0weeks later demonstrated resolution of CSF pleocytosis. Local\u2013regional administration of intraventricular\n                    <jats:sup>131<\/jats:sup>\n                    I-omburtamab targeting B7H3 can result in a profound nucleated CSF pleocytosis with mastocytosis consistent with an acute allergic reaction.\n                  <\/jats:p>","DOI":"10.1007\/s00262-020-02824-0","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T11:04:06Z","timestamp":1612350246000},"page":"2411-2414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3803-878X","authenticated-orcid":false,"given":"Kim","family":"Kramer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa S.","family":"Pessin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"issue":"3","key":"2824_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","volume":"97","author":"K Kramer","year":"2010","unstructured":"Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P et al (2010) Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 97(3):409\u2013418","journal-title":"J Neurooncol"},{"key":"2824_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2741\/e304","volume":"3","author":"MK Nygren","year":"2011","unstructured":"Nygren MK, Tekle C, Ingebrigtsen VA, Fodstad O (2011) B7\u2013H3 and its relevance in cancer; immunological and non-immunological perspectives. Front Biosci (Elite Ed) 3:989\u2013993","journal-title":"Front Biosci (Elite Ed)"},{"issue":"10","key":"2824_CR3","first-page":"4048","volume":"61","author":"S Modak","year":"2001","unstructured":"Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK (2001) Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61(10):4048\u20134054","journal-title":"Cancer Res"},{"issue":"1","key":"2824_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ygyno.2011.09.012","volume":"124","author":"A Brunner","year":"2012","unstructured":"Brunner A, Hinterholzer S, Riss P, Heinze G, Brustmann H (2012) Immunoexpression of B7\u2013H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol 124(1):105\u2013111","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2824_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/SLA.0b013e3181f1939d","volume":"252","author":"T Arigami","year":"2010","unstructured":"Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A et al (2010) B7\u2013h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 252(6):1044\u20131051","journal-title":"Ann Surg"},{"issue":"8","key":"2824_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","volume":"23","author":"X Zang","year":"2010","unstructured":"Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A et al (2010) Tumor associated endothelial expression of B7\u2013H3 predicts survival in ovarian carcinomas. Mod Pathol 23(8):1104\u20131112","journal-title":"Mod Pathol"},{"issue":"5","key":"2824_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1089\/cbr.2005.20.534","volume":"20","author":"S Modak","year":"2005","unstructured":"Modak S, Guo HF, Humm JL, Smith-Jones PM, Larson SM, Cheung NK (2005) Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm 20(5):534\u2013546","journal-title":"Cancer Biother Radiopharm"},{"issue":"8","key":"2824_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","volume":"19","author":"MM Souweidane","year":"2018","unstructured":"Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P et al (2018) Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol 19(8):1040\u20131050","journal-title":"Lancet Oncol"},{"key":"2824_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fimmu.2020.00221","volume":"11","author":"A Taghikhani","year":"2020","unstructured":"Taghikhani A, Farzaneh F, Sharifzad F, Mardpour S, Ebrahimi M, Hassan ZM (2020) Engineered tumor-derived extracellular vesicles: potentials in cancer immunotherapy. Front Immunol 11:221","journal-title":"Front Immunol"},{"key":"2824_CR10","doi-asserted-by":"publisher","first-page":"e55185","DOI":"10.7554\/eLife.55185","volume":"9","author":"AR Lim","year":"2020","unstructured":"Lim AR, Rathmell WK, Rathmell JC (2020) The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife 9:e55185","journal-title":"Elife"}],"updated-by":[{"DOI":"10.1007\/s00262-021-02942-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02824-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02824-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02824-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T09:08:19Z","timestamp":1626685699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02824-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2824"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02824-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"11 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-021-02942-3","URL":"https:\/\/doi.org\/10.1007\/s00262-021-02942-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MSK has institutional financial interests related to this research in the form of intellectual property rights and equity interests in Y-mAbs, the company licensing the intellectual property from MSK. Kim Kramer is a consultant and has equity interests\u00a0in Y-mAbs Therapeutics Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patient (proxy) consented to be treated on IRB-approved protocol registered to clinicaltrials.gov NCT00089245.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}